Research / Clinical Trials
Our practice offers clinical trials which help determine whether newly developed treatments are safe and effective in treating Multiple Sclerosis. These studies are important research tools for the developing new treatment options for this chronic disease. Clinical trials also provide patients with access to new treatment options and new therapies that are not offered to the general population.
As new technologies and therapeutic options become available, Hope Neurology Multiple Sclerosis Center utilizes clinical trials to provide innovative treatment options to our patients.
Clinical research studies provide patients with new medications and access to comprehensive disease management. By working closely with our pharmaceutical sponsors, we strive to improve the health, hope and well-being of our patients.
For more information on any of our studies, please call 865. 218.6222 and ask to speak with Shannon, Stephanie or Geneva or email us at firstname.lastname@example.org
Enrolling Clinical Trials:
ALK8700-A302 – A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
APLIOS COMB157G2102 A 12 Week randomized open label parallel group multicenter study to evaluate bioequivalence of 20mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.
CFTY720DUS40 FLUENT – A 12-Month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS) to investigate changes in immune phenotype biomarkers after treatment with 0.5 fingolimod
PASS OBS13434 – A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis